Genomtec (GMT) Investor Presentation summary

Company overview and team

• Focuses on ultrafast, mobile point-of-care genetic testing platforms using proprietary optical and nucleic acid amplification technologies.

• International team of 20+ experts with locations in Wroclaw, Poland, and Kent, UK.

• Leadership includes experienced professionals in molecular biology, finance, and photonics, with multiple patent authors.

Technology and product portfolio

• SNAAT® technology enables rapid, portable genetic diagnostics for infections and biomarkers at the point of care.

• Genomtec ID platform can diagnose five pathogens with short test times and platform mobility.

• OncoSNAAT project leverages liquid biopsy and LAMP-based methods for detecting genetic variants in oncology.

• 12 patents granted and over 30 patent applications filed, with unique methods for genetic change diagnostics.

OncoSNAAT project and funding

• OncoSNAAT project received PLN 21.6 million in PARP funding, securing development until 2027.

• Project milestones include patent applications for multi- and single-nucleotide variant detection and prototype development.

• LAMP-based method offers high specificity and sensitivity for point-of-care genetic variant detection, validated in scientific publication.